Compare Crispr Therapeutics AG (CRSP) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lithium Americas Corp — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while Lithium Americas Corp trades at $2.35 (market cap $850.38M). The key difference: Crispr Therapeutics AG is far larger — about 5.7× Lithium Americas Corp's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Lithium Americas Corp for 27 Days on average.
| CRSP | LAC | |
|---|---|---|
Market Cap | $4.88B | $850.38M |
Volume | 2,861,747 | 8,804,637 |
Sector | Health | Basic Materials |
52-Week High | $74.92 | $10.05 |
52-Week Low | $44.34 | $2.36 |
Typical Hold Time | 77 Days | 27 Days |
Enterprise Value | $3.30B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Lithium Americas (LAC) trades at $2.34, down 2.9% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company shows negative profitability metrics with ROE at -9.56% and ROA at -3.99%, though it has beaten earnings expectations in recent quarters. Cash flow remains supported by financing activities as the company invests heavily in Thacker Pass development. Analyst consensus is mixed with 7 buy ratings and 8 hold ratings, with a $4.00 price target representing 71% upside potential.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary catalyst is successful construction and operation of Thacker Pass, but investors face significant execution risk, negative cash flow from operations, and lithium price volatility. The stock trades at a discount to book value (P/B 0.6), offering potential upside if operational milestones are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
